TOMATO NEWS
CoughRx-DMX™ Revolutionizes Cold Season: DextroMed's Toothpaste Eliminates Nighttime Coughing
CoughRx-DMX™ Revolutionizes Cold Season: DextroMed's Toothpaste Eliminates Nighttime Coughing
NEW YORK, NY – October 26, 2023 – DextroMed Pharma today announced the launch of CoughRx-DMX™, a groundbreaking toothpaste formulated with a controlled-release dose of dextromethorphan (DMX) designed to eliminate nighttime coughing. This innovative product promises to revolutionize the way people manage cold and flu symptoms, potentially bringing an end to sleepless nights plagued by persistent coughs.
Early user reports indicate a significant reduction, and in many cases, complete elimination of nighttime coughing after using CoughRx-DMX™ as part of their regular bedtime routine. The toothpaste leverages DextroMed's proprietary "Oral Sustained Release Technology" (OSRT) to deliver a low, consistent dose of dextromethorphan throughout the night, providing targeted cough suppression without the daytime drowsiness often associated with traditional cough syrups.
"We recognized a significant unmet need," explains Dr. Anya Sharma, DextroMed's Chief Innovation Officer. "Patients were relying on syrups or tablets that often wore off in the middle of the night, leading to disrupted sleep and prolonged recovery times. CoughRx-DMX™ provides a simple, effective solution by integrating cough relief into a routine everyone already practices: brushing their teeth."
The OSRT technology allows for a metered release of 15mg of DMX over an eight-hour period, significantly lower than the 30mg often found in single doses of over-the-counter cough medications. According to DextroMed’s clinical trials, conducted over a six-month period with a cohort of 250 participants experiencing nocturnal coughs due to upper respiratory infections, 87.4% of participants reported a significant improvement in sleep quality after using CoughRx-DMX™ for three consecutive nights. Moreover, the average reduction in nighttime coughing episodes was 72.9%, compared to a placebo group which saw only a 15.2% reduction.
The toothpaste also contains fluoride for cavity protection and is available in a refreshing mint flavor. While CoughRx-DMX™ is designed to suppress coughs, DextroMed emphasizes that it is not a substitute for addressing the underlying cause of the cough. Users are advised to consult with their healthcare provider if their cough persists for more than seven days or is accompanied by fever, rash, or persistent headache.
"We see CoughRx-DMX™ as a valuable addition to the arsenal against cold and flu symptoms," states Mark Johnson, a pharmacist at a leading drugstore chain in Chicago. "Its unique delivery system offers a convenient and effective way for patients to manage nighttime coughing, allowing them to get the rest they need to recover."
However, the product is not without its critics. Some experts express concern about the potential for overuse or accidental ingestion by children. DextroMed addresses these concerns by including clear warnings and age-appropriate dosage instructions on the packaging. They also plan to launch a public awareness campaign emphasizing responsible use and proper storage.
CoughRx-DMX™ is available now at major pharmacies and online retailers nationwide. A 4.2-ounce tube retails for $9.99. DextroMed is currently exploring expanding the CoughRx line with formulations targeting specific age groups and cough types. The company projects that CoughRx-DMX™ will capture 12.5% of the cough suppressant market within the next year, driven by strong consumer demand and positive clinical trial data. The launch of CoughRx-DMX™ marks a significant step forward in cough management, potentially offering millions relief from the disruptive effects of nighttime coughing during cold and flu season.
No comments:
Post a Comment